CMS Quarterly ASP Updates and Margin Volatility

That sounds simple enough on paper. It isn't, because ASP itself is a moving target.

ASP comes from real transaction data, reported by manufacturers every quarter, and it lags behind the market it's supposed to represent. So the rate a practice gets paid this quarter is really a snapshot of what happened in the drug market some months back, lagging behind what that practice paid to acquire the drug it's billing for today. The rate and the acquisition cost are never on the same clock.

That mismatch is the whole game. The space between what a practice spent to buy a biologic and what Medicare hands back for it is the core margin variable in buy-and-bill infusion, and it shifts every three months, like clockwork. Understanding why it shifts, and how the shift gets calculated, is the starting point for anyone trying to run an infusion practice on purpose rather than by accident.

The quarterly reset calendar from manufacturer to clinic

CMS runs this on a fixed schedule: four ASP pricing files a year, each one governing a specific block of dates of service.

CMS also retroactively corrects payment rates for some drugs on a quarterly basis, posting corrected files on the first day of each quarter. Looking at the CMS ASP pricing file archive, prior quarters get revised well after they were supposedly locked in: both the January 2026 and April 2026 files picked up revisions dated September 8, 2026, months after those quarters had already run their course. A rate a practice billed against in March could get quietly rewritten in September. The July 2026 file covers dates of service July 1–September 30, 2026. The October 2026 file covers dates of service October 1–December 31, 2026, with the final file posted September 18, 2026.

The operational window between when CMS releases a file and when it actually takes effect is tight, and it's worth looking at how tight. Change Request 14521 was issued June 30, 2026, went effective October 1, 2026, and was implemented October 5, 2026. That's the kind of gap a billing team has to track on a calendar, not just assume will sort itself out. The January 2026 file covers dates of service January 1–March 31, 2026. The April 2026 file covers dates of service April 1–June 30, 2026.

What the 2026 rule changes do to the ASP calculation itself

The CY 2026 Physician Fee Schedule final rule, published in the Federal Register on November 5, 2025 and effective January 1, 2026, isn't a routine tune-up. McDermott Will & Emery called it CMS's most comprehensive update in years to how ASP gets reported. The headline change involves something called bundled arrangements. CMS now has a formal definition requiring manufacturers to identify and proportionally spread price concessions across bundled drug purchases, closing a gap in which whole categories of rebates and conditional discounts used to slip through ASP submissions without ever appearing in the number.

That new definition lines up with the standard Medicaid has used for a long time. ASP calculations going forward should track the actual net price manufacturers are receiving, more consistently than before. The practical result: ASP for some drugs may come in lower than it would have under the old rules, because concessions that used to be excluded are now getting captured. Lower ASP means a tighter 106% benchmark. That's a direct line from a methodology change to a smaller check.

Manufacturers also picked up new paperwork obligations. They now have to document their methodology and assumptions in every quarterly ASP submission, and CMS can audit that documentation. Anyone receiving a bona fide service fee has to certify, in writing, that the fee isn't getting passed through to clients or customers.

Starting January 1, 2028, for selected drugs CMS will publish only the new 106% MFP payment limit rather than an ASP-derived rate, while during 2026–2027 the payment limit continues to be ASP-derived. That's happening now. For those selected drugs, CMS will start publishing only the 106% MFP payment limit, with no ASP-derived rate attached at all. Through 2026 and 2027, the payment limit is still built from ASP. The switch to paying off MFP instead of ASP is a 2028 structural change. Different years carry different consequences, and modeling either one requires keeping them apart.

None of this stays inside Medicare's walls, either. Avalere Health's analysis points out that commercial payers and Medicare Advantage plans frequently peg their own drug reimbursement to ASP. So a methodology shift built for Part B ends up rippling into commercial contracts that were never part of the conversation.

The 2028 MFP transition for infusion practices

January 1, 2028 is the date to circle. That's when Part B drugs selected under the Medicare Drug Price Negotiation Program stop being reimbursed at 106% of ASP and start being reimbursed at 106% of MFP minus sequestration. For a practice that runs a heavy volume of negotiated drugs, that is a meaningful share of revenue at stake. It's a structural cut to the payment ceiling on some of the highest-revenue biologics the practice administers.

Avalere Health flags exactly which practices feel this hardest: those running onsite infusion centers with high use of negotiated drugs, a group already under pressure from consolidation and vertical integration that tends to squeeze smaller, independent practices the most. The economics may also push practices toward different acquisition models. Moving to MFP-plus-add-on reimbursement could accelerate a shift away from traditional buy-and-bill toward white-bagging, specialty pharmacy distribution, or self-administered options, each of which comes with its own billing rules and its own margin math.

There's a transparency problem layered on top. CMS is going to suspend ASP publication for negotiated drugs entirely during the MFP period, and ASP won't come back for those drugs until generics or biosimilars show up in the market. That's a real stretch of time where one of the standard contracting benchmarks simply goes dark.

Legislation has been reintroduced that would keep the current ASP+6% model alive by having manufacturers rebate Medicare directly for the MFP gap. Whether that goes anywhere is genuinely unresolved, and it's worth watching rather than counting on. Practices shouldn't build a 2028 plan around a bill that hasn't passed. The window between now and January 1, 2028 is the planning horizon, and practices that begin modeling their drug mix against the negotiated drug list now are better positioned than those that treat this as a future-year problem.

How quarterly rate swings translate into cash-flow risk at the practice level

Buy-and-bill means the practice pays for the drug first and gets reimbursed later, so the acquisition cost is locked in the moment the drug is purchased, while the reimbursement rate depends on whichever ASP file is in effect on the date the drug is actually given. If ASP drops between the quarter a practice bought the drug and the quarter it gets administered, the practice eats that spread, with no way to go back and adjust what it already paid.

At $5,000 to $50,000 per infusion encounter for high-cost specialty biologics, even a small ASP movement turns into real money on a single claim. Multiplying that across a full patient panel and a quarter's worth of appointments turns a modest percentage shift in the ASP file into real, non-abstract money.

Now add denials into that same picture. A denied buy-and-bill claim leaves the practice holding the full cost of a drug it already bought and already gave to a patient, with zero reimbursement coming back. A quarter where ASP happened to fall turns a single denied claim on a high-cost biologic into a compounded loss, not just a missed payment.

Billing against whatever rate the Medicare Administrative Contractor happens to apply, and hoping it holds, isn't a strategy anyone can afford when the underlying rate resets four times a year and gets revised retroactively on top of that. The volatility is baked into the system. What a practice does about it is the only variable left in its control.

Where billing execution determines whether the practice captures its entitled rate

Billing mistakes in this environment are a direct drain on revenue that compounds over time. They're permanent write-offs on drugs the practice already paid for out of pocket, and the ASP system doesn't leave much room to fix them after the fact.

Start with something as basic as the billing code itself. CMS has rejected claims submitted with discontinued HCPCS codes since January 1, 2010, and any code discontinued as of December 31, 2025 becomes invalid the moment 2026 dates of service roll around. If a practice's billing system and charge master aren't updated to match each quarter's code changes, claims bounce automatically, before a payer ever even looks at them.

J-code unit accuracy matters just as much, and it's an easy place to get burned. J-code descriptors specify exact metric units, things like "per 10 mg" or "per 1 mg," and a unit error on a high-cost biologic compounds fast. Overbill the units and a practice is looking at audit exposure. Underbill them and that revenue is gone for good, with no do-over.

Coding mismatches between the drug code and the administration code are another concentrated source of denials. Pairing an intravenous J-code with a subcutaneous injection CPT code is one common failure. So is multiplying CPT administration units off the drug's milligram count instead of following the correct time-based hierarchy, and so is picking the wrong "initial" versus "sequential" code on an infusion administration claim.

JW and JZ modifiers, used to report drug waste from single-dose vials, have come under tighter audit scrutiny. Without regular reconciliation between what the pharmacy actually dispensed and what billing actually submitted, a practice runs the risk of overbilling and underbilling at the same time, on different claims. Nationwide, claim denial rates run around 20% across all claim types, with medication-related and prior-authorization denials among the fastest-growing categories, and infusion and injectable drug services sitting among the highest-risk areas under Medicare Part B oversight. None of that is abstract risk. It's dollars already spent on drugs already administered, waiting to be collected or lost.

Prior authorization as the upstream control point for margin protection

By the time a claim gets submitted, a lot of the margin has already been decided, one way or the other, back at the authorization stage. Prior authorization denial rates climbed sharply in 2026, and high-complexity specialty infusion and biologics drove a large share of that increase, which makes sense given how much financial incentive payers have to scrutinize every step of an expensive treatment.

Almost every specialty infusion drug needs prior authorization before the first dose goes in, and that authorization has to spell out the exact drug, dose, frequency, and duration. The authorization also expires, not just requiring the drug, dose, frequency, and duration to be spelled out. Payers typically require renewal every three to six months, and a treatment given after that authorization lapses gets treated exactly like a treatment given with no authorization at all: a full denial. Tracking expiration dates is a direct margin-protection function. It's a direct margin-protection function.

Some relief showed up in the rules starting January 1, 2026: insurers can no longer require step therapy at all for drugs treating multiple sclerosis or rheumatoid arthritis.

The real revenue leak sits in what happens after a denial, though, and the numbers here are stark. More than 80% of prior authorization appeals to Medicare Advantage plans get overturned when someone actually appeals them. Only about 20% of physicians consistently follow through on filing those appeals. A large share of denials just never get contested at all. That gap between what would get overturned and what actually gets appealed reflects a pattern of decisions within the practice's control. It's a choice practices are making, whether they realize it or not.

Payers now have to publish their own aggregated prior authorization numbers, covering approval rates, denial rates, average turnaround time, and appeal outcomes, for calendar year 2025, with that data due by March 31, 2026. That's new leverage. For the first time, a practice can compare payer performance on paper before deciding where to push back hardest.

Denial patterns in infusion are not random, they concentrate by payer, therapy, and root cause

Denials in oncology and infusion run 18 to 20 percentage points higher than in primary care, and that gap reflects a consistent pattern. It's a signal pointing directly at where payers have the strongest financial reason to deny a claim: the most expensive treatments, administered to the sickest patients, at the highest dollar amounts per encounter.

Prior authorization mismatches, drug-to-diagnosis inconsistencies, coverage eligibility that lapsed without anyone noticing, and timely filing failures on secondary claims are the handful of root causes visible in any mid-market infusion organization's denial data. These aren't scattered randomly across the business. They cluster, by payer, by therapy type, and often by the specific site delivering care. A denial problem that looks like chaos when you zoom out turns into a short, specific list of failure modes once you zoom back in.

Most of the denials worth real money come down to procedural issues. They're procedural: missing documentation showing conservative treatment was tried first, step therapy criteria that weren't met, coding mismatches, or a diagnosis code that doesn't support the procedure under that particular plan's policy. Site-of-care denials add a separate pressure of their own. Payers increasingly deny hospital outpatient claims when the same treatment could have been delivered in an ambulatory surgery center or a patient's home, and as site-neutral payment rules keep advancing, that pressure is only going to build.

Specialty drugs and buy-and-bill infusions already carry processing times of one to three weeks, driven by medical benefit review and site-of-care policy checks. That's a long runway for accounts receivable to age on claims that are already carrying the highest dollar amounts in the practice. Treated as a management problem rather than a fact of life, though, these patterns are exactly specific enough to fix, and platforms like Ruby RCM, a revenue cycle management tool built specifically for infusion centers that handles prior authorizations, denial management, and AR for buy-and-bill practices, are designed around that granularity rather than general-purpose billing assumptions.